Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Investigating FadD32 as a Target for 7-Substituted Coumarin Derivatives and Other Potential Antimycobacterial Agents.

Current drug delivery·2026
Same author

Transitioning regulatory authorities in South Africa: a comparative review of the organisational structure and management practices.

Journal of pharmaceutical policy and practice·2026
Same author

Nanomedicine Solutions for Alzheimer's Disease: A Critical Review of Therapeutic Nanoparticle Strategies.

ACS omega·2025
Same author

Dual GSK3β/SIRT1 modulators for Alzheimer's: mechanisms, drug discovery and future perspectives.

Frontiers in pharmacology·2025
Same author

HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents.

Expert opinion on therapeutic patents·2024
Same author

NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders.

Pharmaceuticals (Basel, Switzerland)·2024

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Thabo Brighton Makgoba1, Jacques Joubert2, Erika Kapp1

  • 1University of the Western Cape, Cape Town, Western Cape, South Africa.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 26, 2025
PubMed
概括

这项研究使用in silico方法确定了针对基因素脱乙酶3 (HDAC3) 的新型化合物. 需要进一步优化,以提高潜在的治疗应用的功效,选择性和安全性.

科学领域:

  • 表观遗传学和分子生物学
  • 药用化学 医学化学
  • 计算机化药物发现技术

背景情况:

  • 基因脱乙酶 (HDACs) 调节基因表达,并与各种疾病有关.
  • 第I类HDACs,特别是HDAC3,是治疗干预的目标,但非选择性抑制会导致副作用.
  • 现有的HDAC3抑制剂经常面临着强度,选择性和毒性方面的挑战,需要新的方法.

研究的目的:

  • 确定具有独特结合组 (ZBGs) 的新型基因素脱乙酶3 (HDAC3) 选择性抑制剂.
  • 通过计算来选各种化合物库的潜在HDAC3抑制剂.
  • 为开发更安全,更有效的HDAC3向疗法奠定基础.

主要方法:

  • 在 silico 工具中使用 (PROCHECK,VERIFY3D,分子操作环境,ProteinsPlus,Schrodinger Maestro) 用于蛋白质结构验证,活性位点预测和分子对接.
  • 对聚焦的复合库进行了基于结构的虚拟选.
  • 使用重新对接和主动/诱集的基准对接协议,以确保可靠性.

主要成果:

  • 查发现了22种不同的化合物,其中11种在体外表现出抑制HDAC3的活性.
  • 化合物"a"显示出强大的HDAC3抑制 (IC50 0.99μM),但缺乏选择性,并预测了毒性.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451
  • 化合物"b"表现出中度的HDAC3抑制 (IC50 15.5μM),与HDAC1/2相比选择性得到改善,并预测有毒性,而这两种化合物预测是不穿透血脑屏障 (BBB) 的.
  • 结论:

    • 成功识别出具有HDAC3抑制潜力的新型化合物.
    • 突出了结构优化的关键需求,以改善抑制活性和选择性.
    • 强调加强血脑屏障 (BBB) 透性和减轻未来药物开发预测毒性的重要性.